MedTrace Logo

Shanghai Clinical Cohort - Parkinson's Disease (Reserve)

NCT07353463 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2026-03-05

No results posted yet for this study

Summary

The goal of this observational cohort studyis to establish a high-quality clinical cohort of Parkinson's disease (PD) and multiple system atrophy (MSA) patients in Shanghai, in order to improve early diagnosis, precise subtyping, disease monitoring, and to provide a resource for translational research and novel therapy development.

The main questions it aims to answer are:

* Can multimodal data (clinical, imaging, electrophysiology, biospecimens, and genetics) help identify early biomarkers for PD and MSA?
* Can precise subtyping and long-term monitoring predict disease progression and therapeutic response? Researchers will compare 600 PD patients and 100 MSA patients to evaluate differences in clinical features, biomarkers, imaging, and prognosis.

Participants will:

* Provide informed consent and complete baseline demographic and medical history collection.
* Undergo standardized clinical evaluations, including motor and non-motor symptom scales, cognitive and quality-of-life assessments.
* Provide biological samples (blood, saliva, optional CSF).
* Receive brain imaging (MRI, optional PET/SPECT) and electrophysiological recordings (EEG, fNIRS).
* Participate in longitudinal follow-up visits every 6 months for repeat assessments.

This study will create a sustainable, multicenter, and sharable cohort platform to support early identification, personalized intervention, and therapeutic development for neurodegenerative diseases

Conditions

Sponsors & Collaborators

  • Huashan Hospital

    collaborator OTHER

  • Shanghai Yangzhi Rehabilitation Hospital

    collaborator UNKNOWN

  • Longhua Hospital

    collaborator OTHER

  • Shanghai Municipal Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

    collaborator OTHER

  • Ruijin Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07353463 on ClinicalTrials.gov